A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

Phase 1 Completed 32 enrolled Portola Pharmaceuticals Merck Sharp & Dohme LLC · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.

Timeline

Start: 2009-07-31
Primary completion: 2010-02-28
Completion: 2010-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Betrixaban	Small molecule	80 mg	Oral

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

Summary

Timeline

Drugs

Indications